【CLAIMS】

1. A pharmaceutical composition for prevention or treatment of osteoarthritis, comprising a transformed mammalian cell population, wherein cells or cell groups included in the population have a particle diameter D_{90} of less than 200 μm.

2. The composition according to claim 1, wherein the transformed mammalian cell population is further treated by irradiation.

3. The composition according to claim 1, further comprising an untransformed mammalian cell population in addition to the transformed mammalian cell population.

4. The composition according to claim 3, wherein the cells or cell groups included in the untransformed mammalian cell population have a particle diameter D_{90} of less than 300 μm.

5. The composition according to claim 3, wherein the untransformed mammalian cell population and the transformed mammalian cell population are mixed in a mixing ratio of 1 to 10 : 1 based on the number of cells.

6. The composition according to claim 1, wherein the mammalian cell is a chondrocyte or a chondroprogenitor cell.

7. The composition according to claim 1, wherein the mammalian cell is transformed with a transforming growth factor beta (TGF-β).

8. A kit for preparation of a cell therapeutic agent, comprising a mammalian cell population transformed with a transforming growth factor beta (TGF-β), wherein cells or cell groups included in the population have a particle diameter D_{90} of less than 200 μm.

9. The kit according to claim 8, further comprising an untransformed mammalian cell population in addition to the transformed mammalian cell population.

10. The kit according to claim 9, wherein the cells or cell groups included in the untransformed mammalian cell population have a particle diameter D_{90} of less than 300 μm.

11. The composition according to claim 9, wherein the untransformed mammalian cell population and the transformed mammalian cell population are mixed in a mixing ratio of 1

to 10 : 1 based on the number of cells.

12. A method for manufacturing an osteoarthritis therapeutic agent, comprising the steps of:

(1) preparing a transformed mammalian cell population with TGF-β and an untransformed mammalian cell population, respectively;

(2) selecting cells or cell groups having a particle diameter D_{90} of less than 200 μm included in the transformed mammalian cell population with TGF-β in the above step (1); and cells or cell groups having a particle diameter D_{90} of less than 300 μm included in the untransformed mammalian cell population, respectively;

(3) filling a separate vial with both of the selected cell populations in step (2), respectively; and

(4) mixing the selected cell populations in the vial in step (3).

13. The method according to claim 12, wherein the mixing in step (4) is to mix the untransformed mammalian cell population and the transformed mammalian cell population in step (2) in a mixing ratio or 1 to 10 : 1 based on the number of cells.

14. The method according to claim 12, wherein the

transformed mammalian cell population with TGF-β in step (1) is further irradiated.

15. The composition according to claim 1, wherein the mammalian cell is transformed with a transforming growth factor beta (TGF-β).